VivoSeq
Respiratory

Acute Respiratory Failure

25

Pipeline Programs↗

9

Active Trials↗

13

Companies Involved↗

Acute Respiratory Failure is an emerging landscape with 25 programs across 13 companies. The most active players are Ono Pharmaceutical Co. Ltd, AstraZeneca, Sanofi. 1 therapy is approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

22/100

Mech. Concentration

8/100

Completion Rate

71/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

24 of 27 classified programs — the dominant modality here.

11%ALL OTHERSProtein / enzyme27%Monoclonal antibody14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed12 · 41%
Recruiting4 · 14%
Terminated4 · 14%
Not yet recruiting4 · 14%
Unknown status3 · 10%
Withdrawn1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

29 trials

Anticoagulation-free VV ECMO for Acute Respiratory Failure
Recruiting·—·Phase 2/3·NCT04273607·40 enrolled
Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure
Recruiting·—·Phase 2·NCT06319274·450 enrolled
Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
Recruiting·SSouth West Sydney Local Health District·Phase 2·NCT05540834·70 enrolled
Proteomic Analysis of Exhaled Breath Condensate in Mechanically Ventilated Intensive Care Patients
Recruiting·TThe Institute of Molecular and Translational Medicine, Czech Republic·N/A·NCT06189924·200 enrolled
Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC
Not yet recruiting·UUniversità degli Studi di Ferrara·Phase 2/3·NCT06815679·20 enrolled
Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia
Not yet recruiting·—·Phase 1/2·NCT07357935·500 enrolled
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT06881927·212 enrolled
Effect of Nicardipine and Nitroglycerin on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Using Electrical Impedance Tomography: A Prospective Pilot Study
Not yet recruiting·FFirst Affiliated Hospital of Wannan Medical College·Preclinical·NCT07603037·12 enrolled
Hyperangulated Versus Standard Geometry Laryngoscope Blade Trial
Enrolling by invitation·VVanderbilt University Medical Center·Preclinical·NCT07223762·2,500 enrolled
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Completed·VVirginia Commonwealth University·Phase 2·NCT04463004·2 enrolled
Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)
Completed·HHelsinki University Central Hospital·Phase 2/3·NCT01713309·59 enrolled
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04357457·181 enrolled
Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia
Completed·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 2·NCT00417326·174 enrolled
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Completed·VVanderbilt University Medical Center·Phase 3·NCT01739933·438 enrolled
Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure
Completed·PPeking Union Medical College Hospital·Phase 2/3·NCT04244591·80 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)